Hepatitis C virus infection in Scotland: Epidemiological review and public health challenges

Scottish Medical Journal

Volumn 51, Issue 2, 2006, Pages 8-15

  Hutchinson, Sharon J ^a,b   Roy, K M ^a   Wadd, S ^a   Bird, S M ^b,c   Taylor, A ^d   Anderson, E ^a   Shaw, L ^a   Codere, G ^a   Goldberg, D J ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

Burden; Diagnosis; Hepatitis C; Prevalence; Prevention

Indexed keywords

ANTIVIRUS AGENT; METHADONE;

BLOOD DONOR; CHILDHOOD DISEASE; CHRONIC DISEASE; DIAGNOSTIC ERROR; DISEASE SEVERITY; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; INFORMATION PROCESSING; INTRAVENOUS DRUG ABUSE; LIVER FAILURE; MAINTENANCE THERAPY; PREDICTION; PREGNANCY; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRISONER; PUBLIC HEALTH; REVIEW; UNITED KINGDOM;

EID: 33646565293     PISSN: 00369330     EISSN: 00369330     Source Type: Journal    
DOI: 10.1258/RSMSMJ.51.2.8     Document Type: Review

References (61)

1. World Health Organisation. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. Tibbs CJ. Methods of transmission of hepatitis C. J Viral Hepat 1995; 2: 113-9.
4. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
5. Lim JK. Natural history of hepatitis C infection: a concise review. Yale J Blot Med 2001; 74: 229-37.
6. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
7. Fried MW, Shiffman ML, Reddy KR et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C. N Engl J Med 2002; 347: 975-82.
8. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
9. National Institute for Clinical Excellence. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. (Available at http://www.nice.org.uk/pdf/FAD_HepC.pdf. Accessed 6th April 2006)
10. Booth JCL, O'Grady J, Neuberger J, on behalf of the Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001; 49 (Suppl. 1); 11-21.
11. Chisholm M. Member's Debate on Hepatitis C, 30th June. Scottish Parliament, Edinburgh 2004.
12. Codere G, Shaw L, Goldberg D. Surveillance of known hepatitis C antibody positive cases in Scotland: results to 31 December 2003. SCIEH Weekly Report 2004; 38 (26):150-5.
13. Health Protection Agency, SCIEH, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, and the UASSG. Shooting Up; Infections among injecting drug users in the United Kingdom 2003. London: Health Protection Agency, October 2004.
14. Hutchinson SJ, Goldberg DJ, King M et al. Hepatitis C virus among childbearing women in Scotland: prevalence, deprivation, and diagnosis. Gut 2004; 53: 593-8.
15. Ades AE, Parker S, Walker J et al. HCV prevalence in pregnant women in the UK. Epidemiol Infect 2000; 125: 399-405.
16. European Paediatric HCV Network, Pembrey L, Newell M-L, Tovo P-A. Antenatal hepatitis C virus screening and management of infected women and their children: policies in Europe. Eur J Pediatr 1999; 158: 842-6.
17. Bohman VR, Stettler RW, Little BB et al. Seroprevalence and risk factors for hepatitis C virus antibody in pregnant women. Obstet Gynecol 1992; 80: 609-13.
18. Leikin EL, Reinus JF, Schmell E et al. Epidemiologic predictors of hepatitis C virus infection in pregnant women. Obstet Gynecol 1994; 84: 529-34.
19. Silverman NS, Snyder M, Hodinka RL et al. Detection of hepatitis C virus antibodies and specific hepatitis C virus ribonucleic acid sequences in cord bloods from a heterogeneous prenatal population. Am J Obstet Gynecol 1995; 173: 1396-400.
20. Garner JJ, Gaughwin M, Dodding J et al. Prevalence of hepatitis C infection in pregnant women in South Australia. MJA 1997; 166: 470-2.
21. Goldberg D, McIntyre PG, Smith R et al. Hepatitis C virus among high and low risk pregnant women in Dundee: unlinked anonymous testing. BJOG 2001; 108: 365-70.
22. Chatzipantazi P, Roy W, Cameron SO et al. The feasibility and acceptability of collecting oral fluid from healthy children for anti-HCV testing. Arch Dis Child 2004; 89: 185-7.
23. Dow BC. Surveillance of blood-borne infections in donated blood, Scotland 2003. HPS Weekly Report 2005; 39 (3): 21-2.
24. Crawford RJ, Gillon J, Yap PL et al. Prevalence and epidemiological characteristics of hepatitis C in Scottish blood donors. Transfus Mod 1994; 4: 121-4.
25. Health Protection Agency. Surveillance of viral infections in donated blood, England and Wales: 2003. CDR Weekly 2004; 14 (44).
26. Zou S, Noted EP 4th, Stramer SL, Wahab F, Musavi F, Dodd RY; ARCNET Research Group. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study, Transfusion 2004; 44: 1640-7.
27. Watson HG, Ludlam CA, Rebus S et al. Use of several second generation serological assays to determine the true prevalence of hepatitis C infection in haemophiliacs treated with non-virus inactivated factor VIII and XI concentrates. Br J Haemat 1992; 80: 514-8.
28. Lowe GD. Haemophilla, blood products and HIV infection. Scott Med J 1987; 32: 109-11.
29. McIntyre PG, McCruden EA, Dow BC et al. Hepatitis C virus infection in renal dialysis patents in Glasgow. Nephrol Dial Transplant 1994; 9: 291-5.
30. Thorburn D, Roy K, Cameron SO, Johnston J et al. Risk of hepatitis C virus transmission from patients to surgeons: model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow. Gut 2003; 52: 1333-8.
31. Haydon GH, Jarvis LM, Simmonds P et al. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut 1997; 40: 128-32.
32. Thorburn D, Dundas D, McCruden EAB et al. A study of hepatitis C prevalence in healthcare workers in the West of Scotland. Gut 2001; 48: 116-20.
33. Zuckerman J, Clewley G, Griffiths P et al. Prevalence of hepatitis C antibodies in clinical health-care workers. Lancet 1994; 343: 1618-20.
34. Neal KR, Doman J, Irving WL. Prevalence of hepatitis C antibodies among healthcare workers of two teaching hospitals. Who is at risk? BMJ 1997; 314: 179-80.
35. Roy K, Kennedy C, Bagg J et al. Hepatitis C infection among dental personnel in the West of Scotland, UK. J Hosp Infect 2003; 55: 73-6.
36. Goldberg D, Cameron S, Sharp G et al. Hepatitis C virus among genitourinary clinic attenders in Scotland: unlinked anonymous testing. Int J STD & AIDS 2001; 12: 17-21.
37. Wyld R, Robertson JR, Brefile RP et al. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997; 35: 163-6.
38. Gore SM, Bird AG, Cameron SO et al. Prevalence of hepatitis C in prisons: WASH-C surveillance linked to self-reported risk behaviours. QJ Med 1999; 92: 25-32.
39. Champion JK, Taylor A, Hutchinson S et al. Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study. Am J Epidemiol 2004; 159: 514-9.
40. Gore SM, Brettle RP, Burns SM et al. Pilot study to estimate survivors to 1995 of 1983-84 prevalent hepatitis C infections in Lothian patients who tested positive or negative for hepatitis B surface antigen in 1983-84. J Infect 1998; 37: 159-65.
41. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. J Epidemiol Biostat 2001; 6: 243-65.
42. Taylor A, Goldberg D, Hutchinson S et al. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infection 2000; 40: 1-8.
43. Brettle RP. HIV and harm reduction for injecting drug users. AIDS 1991; 5: 125-36.
44. Stimson G. AIDS and injecting drug use in the United Kingdom 1987-1993: the policy response and the prevention of the epidemic. Soc Sci Med 1995; 41: 699-716.
45. Hutchinson SJ, McIntyre PG, Molyneaux P et al. Prevalence of hepatitis C among injectors in Scotland 1989-2000: declining trends among young injectors halt in the late 1990s. Epldemiol Infect 2002; 128: 473-7.
46. Taylor A, Goldberg D, Hutchinson S et al. High risk injecting behaviour among injectors from Glasgow: cross-sectional community wide surveys 1990-1999. J Epidemiol Community Health 2001; 55: 766-7.
47. Hutchinson SJ, Bird SM, Taylor A et al. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int J Drug Policy (in press)
48. Shaw L, Taylor A, Roy KM et al. Establishment of a database of a diagnosed HCV-infected persons in Scotland. Commun Dis Public Health 2003; 6: 305-10.
49. Codere G, McLeod A, Shaw L et al. Surveillance of known hepatitis C antibody positive cases in Scotland: Results to 30 June 2005. HPS Weekly Report 2005; 39 (2005/50): 278-82.
50. Hutchinson SJ, Bird SM, Goldberg DJ. Modelling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42; 711-23.
51. Wong JB, McQuillan GM, McHutchison JG et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
52. Davis GL, Albright JE, Cook SF et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
53. Deuffic-Burban S, Wong JB, Valleron A-J et al. Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatology 2004; 40: 319-326.
54. Sagmeister M, Renner EL, Mullhaupt B et al. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol & Hepatol 2002; 14: 25-34.
55. Scottish Executive Health Department Letter 2002 (75). Hepatitis C Infected Health Care Workers. (Available at http://www.show.scot.nhs.uk/ sehd/mels/(HDL2002_75.pdf. Accessed 6th April 2006)
56. Hay JE. Viral Hepatitis in Pregnancy. Viral Hepatitis Reviews 2000; 6: 205-15.
57. MacLean AB, Cameron S, Follett EAC. Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age. BJOG and Gynaecology 1993; 100: 702-3.
58. Peat M, Budd J, Burns SM, Robertson R. Audit of bloodborne virus infections in injecting drug users in general practice. Commun Dis Public Health 2000; 3: 244-6.
59. McCruden EAB, Hillan KJ, McKay IC et al. Hepatitis virus infection and liver disease in injecting drug users who died suddenly. J Clin Pathol 1996; 552-5.
60. Stevenson J, Tannahill M, Biggs V on behalf of the outbreak control team. An outbreak of acute hepatitis B infection among injecting drug users in Inverclyde, Scotland. Commun Dis Public Health 2001; 4: 60-3.
61. Hay G, McKeganey N, Hutchinson SJ, on behalf of the project team. Estimating the national and local prevalence of problem drug misuse in Scotland. Edinburgh: ISD, 2001.